In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells

Biochemical Pharmacology

Volumn 72, Issue 3, 2006, Pages 308-319

  Chen, Yi Lin ^a,b   Lin, Shinn Zong ^a,b   Chang, Jang Yang ^c   Cheng, Yeung Leung ^e   Tsai, Nu Man ^a,b,f   Chen, Shee Ping ^a,b   Chang, Wen Liang ^d   Harn, Horng Jyh ^a,b  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^f ASIA UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Bupleurum scorzonerifolium; Cell cycle arrest; Isochaihulactone; Microtubule destabilizing

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; ISOCHAIHULACTONE; LIGNAN; PROTEIN; PROTEIN CDC25C; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CARBON NUCLEAR MAGNETIC RESONANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DOWN REGULATION; DRUG ISOLATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFRARED RADIATION; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN POLYMERIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR CELL LINE; TUMOR XENOGRAFT;

4-BUTYROLACTONE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZODIOXOLES; BUPLEURUM; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE; HUMANS; INHIBITORY CONCENTRATION 50; LIGNANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, FLUORESCENCE; MICROTUBULES; PHOSPHORYLATION; PLANT EXTRACTS; PLANT ROOTS; TUBULIN; WEIGHT GAIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33745649582     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.04.031     Document Type: Article

References (44)

1. Eisenberg D.M., Davis R.B., Ettner S.L., Wilkey S., Van Rompay M., and Kessler R.C. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. J Am Med Assoc 280 (1998) 1569-1575
2. Wang L.G., Liu X.M., Kreis W., and Budman D.R. The effects of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44 (1999) 355-361
3. Jordan A., Hadfield J.A., Lawrence N.J., and McGown A.T. Tubules as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 18 (1998) 219-248
4. Kuo C.C., Hsieh H.P., Pan W.Y., Chen C.P., Liou J.P., Lee S.J., et al. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 64 (2004) 4621-4628
5. Schwartsmann G., Ratain M.J., Cragg G.M., Wang G.E., Saijo N., and Parkinson D.R. Anticancer drug discovery and development throughout the world. J Clin Oncol 20 (2002) 47S-59S
6. Kelly K., Lovato L.P.J., Livingston R.B., Zangmeister J., Taylor S.A., Roychowdhury D., et al. Southwest Oncology Group. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group. Clin Cancer Res 7 (2001) 2325-2329
7. Zou Y., Fu H., Ghosh S., Farquhar D., and Klostergaard J. Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin Cancer Res 10 (2004) 7382-7391
8. Kragelj B., Zaletel-Kragelj L., Sedmak B., Cufer T., and Cervek J. Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol 75 (2005) 44-47
9. Kugler A., Haschemi R., Zoller G., Gross A.J., Kallerhoff M., and Ringert R.H. Anticancer drug discovery and development throughout the world. Urol Res 25 (1997) 240-250
10. Lu da Y., Huang M., Xu C.H., Yang W.Y., Hu C.X., Lin L.P., et al. Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines. BMC Pharmacol 20 (2005) 1-11
11. Schwartsmann G., Ratain M.J., and Cragg G.M. Anticancer drug discovery and development throughout the world. J Clin Oncol 20 (2002) 47S-59S
12. Jemal A., Thomas A., Murray T., and Thun M. Cancer statistics, 2002. CA Cancer J Clin 52 (2002) 23-47
13. Cheng Y.L., Chang W.L., Lee S.C., Liu Y.G., Chen C.J., Lin S.Z., et al. Acetone extract of Angelica sinensis inhibits proliferation of human cancer cells via inducing cell cycle arrest and apoptosis. Life Sci 75 (2004) 1579-1594
14. Kao S.T., Yeh C.C., Hsieh C.C., Yang M.D., Lee M.R., and Liu H.S. The Chinese medicine Bu-Zhong-Yi-Qi-Tang inhibited proliferation of hepatoma cell lines by inducing apoptosis via G0/G1 arrest. Life Sci 69 (2001) 1485-1496
15. Vickers A. Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials. Cancer Invest 20 (2002) 1069-1079
16. Cheng Y.L., Chang W.L., Lee S.C., Liu Y.G., Lin H.C., Chen C.J., et al. Acetone extract of Bupleurum scorzonerifolium inhibits proliferation of A549 human lung cancer cells via inducing apoptosis and suppressing telomerase activity. Life Sci 73 (2003) 2383-2394
17. Cheng Y.L., Lee S.C., Lin S.C., Chang W.L., Chen Y.L., Tsai N.M., et al. Anti-proliferative activity of Bupleurum scrozonerifolium in A549 human lung cancer cells in vitro and in vivo. Cancer Lett 222 (2005) 183-193
18. Martello L.A., Verdier-Pinard P., Shen H.J., He L., Torres K., Orr G.A., et al. Elevated level of microtubule destabilizing factors in a taxol-resistant/dependent A549 cell line with α-tubulin mutation. Cancer Res 63 (2003) 448-454
19. Chang J.Y., Chang C.Y., Kuo C.C., Chen L.T., Wein Y.S., Kuo Y.H., et al. A novel microtubule inhibitor isolated from Salvia miltiorrhizea Bunge (Danshen) with antimitotic activity in multidrug-sensitive and resistant human tumor cells. Mol Pharmcol 65 (2004) 77-84
20. Hosono S., Lee C.S., Chou M.J., Yang C.S., and Shih C.H. Molecular analysis of the p53 alleles in primary hepatocellular carcinomas and cell lines. Oncogene 6 (1999) 237-243
21. Mickisch G., Fajta S., Keilhauer G., Schlick E., Tschada R., and Alken P. Chemosensitivity testing of primary human renal cell carcinoma by a tetrazolium based microculture assay (MTT). Urol Res 18 (1990) 131-136
22. Bollag D.M., McQueney P.A., and Zhu J. Epothilone, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55 (1995) 2325-2333
23. Blagosklonny D.M., Schulte T.W., Nguyen P., Mimnaugh E.G., Trepel J., and Neckrs L. Taxol induction of p21/WAF1 and p53 requires c-raf-1. Cancer Res 55 (1995) 4623-4626
24. van Engeland M., Ramaekers F.C., Schutte B., and Reutelingsperger C.P. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31 (1998) 1-9
25. Krajewski S., Tanaka S., Takayama S., Schibler M.J., Fenton W., and Reed J.C. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53 (1993) 4701-4714
26. Dumontet C., and Sikic B.I. Mechanisms of action of the resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17 (1999) 1061-1070
27. Deng L., Tatebe S., Lin-Lee Y.C., Ishikawa T., and Kuo M.T. MDR and MRP gene families as cellular determinant factors for resistant to clinical anticancer agents. Cancer Treat Res 112 (2002) 49-66
28. Downing K.H., and Nogales E. Crystallographic structure of tubulin: Implication for dynamics and drug binding. Cell Struct Funct 24 (1999) 269-275
29. Bai R., Davidm D.G., Pei X.F., Ewelli J.B., Nguyeni N.Y., Brossi A., et al. Mapping the binding site of colchicinoids on β-tubulin. J Biol Chem 22 (2000) 40443-40452
30. Ravelli B.G., Gigant B., Curmi P.A., Jourdain I., Lachkar S., Sobel A., et al. Insight into tubulin regulation from a complex with colchicines and a stathmin-like domain. Nature 11 (2004) 428
31. Gigant B., Curmi P.A., Jourdain I., Charbaut E., Lachkar S., Lebeau L., et al. The 4 Å X-ray structure of a tubulin:stathmin-like domain complex. Cell 102 (2000) 809-816
32. WAF1/CIP response to genotoxic agents in wild type TP53 expression breast primary tumors. Oncogene 14 (1997) 45-52
33. Bulavin D.V., Higashimoto Y., Demidenko Z.N., Meek S., Graves P., Phillips C., et al. Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol 5 (2003) 545-551
34. + protein kinase regulates entry into mitosis. Nature 342 (1989) 39-45
35. Lammer C., Wagerer S., Saffrich R., Mertens D., Ansorge W., and Hoffmann I. The cdc25B phosphatase is essential for the G2/M phase transition in human cells. J Cell Sci 111 (1998) 2445-2453
36. Singh R.P., Agrawal P., Yim D., Agarwal C., and Agarwal R. Acacetin inhibits cell growth and cell cycle progression, and induces apoptosis in human prostate cancer cells: structure-activity relationship with linarin and linarin acetate. Carcinogenesis 26 (2005) 845-854
37. Susin S.A., Lorenzo H.K., and Zamzami N. Mitochondrial release of caspase-2 and caspase-9 during the apoptosis process. J Exp Med 189 (1999) 381-394
38. Slee E.A., Harte M.T., Kluck R.M., Wolf B.B., Casiano C.A., and Newmeyer D.D. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8 and -10 in a caspase-9 dependent manner. J Cell Biol 144 (1999) 281-292
39. Du L., Lyle C.S., and Chambers T.C. Characterisation of vinblastine induced BCL-XL and BCL-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction. Oncogene 24 (2005) 107-117
40. Liao C.H., Pan S.L., Guh J.H., Chang Y.L., Pai H.C., Lin C.H., et al. Antitumor mechanism of evodiamine, a constituent from Chinese herb Edodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis 26 (2005) 968-975
41. Franklin J., and Diehl V. Current clinical trails for the treatment of advanced-stage Hodgkin's disease: BEACOPP. Ann Oncol 13 (2002) 98-101
42. Kolb E.A., and Steinherz P.G. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia 17 (2003) 1962-1972
43. Rebert C.S., Pryor G.T., and Frick M.S. Effects of vincristine, maytansine and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat. J Appl Toxicol 4 (1984) 330-338
44. Chae L., Moon H.S., and Kim S.C. Overdose of vincristine: experience with a patient. J Korean Med Sci 13 (1998) 334-338